Data / Drug companies / Microtubule Inhibitor
Microtubule Inhibitor drugs: 7 drugs from 50 companies in the FDA NDC directory
Microtubule Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 133 products in this class from 50 companies, covering 7 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on October 19, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 50Companies
- 133Products
- 7Drugs by generic name
Drugs in the Microtubule Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Docetaxel | 56 | 21 |
| Paclitaxel | 41 | 20 |
| Eribulin mesylate | 18 | 17 |
| Docetaxel anhydrous | 14 | 5 |
| Paclitaxel protein-bound particles | 2 | 2 |
| Paclitaxel (aibumin-bound) | 1 | 1 |
| Tirbanibulin | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Hospira, Inc. | 11 | injection, solution | New drug applications (NDA) | January 10, 2022 |
| Gland Pharma Limited | 7 | injection; injection, solution | Generic drugs (ANDA) | April 5, 2024 |
| Teva Parenteral Medicines, Inc. | 7 | injection, solution, concentrate | Generic drugs (ANDA) | July 7, 2020 |
| Baxter Healthcare Corporation | 6 | injection, solution; injection | New drug applications (NDA) | November 27, 2025 |
| Dr. Reddy's Laboratories Inc. | 6 | injection, solution; injection | Generic drugs (ANDA) | January 22, 2026 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 6 | injection, solution; injection | Generic drugs (ANDA) | December 15, 2024 |
| Meitheal Pharmaceuticals Inc. | 5 | injection, solution, concentrate; injection | Generic drugs (ANDA) | October 19, 2026 |
| Mylan Institutional LLC | 5 | injection, solution; injection, solution, concentrate | Generic drugs (ANDA) | October 9, 2025 |
| Alembic Pharmaceuticals Inc. | 4 | injection | Generic drugs (ANDA) | February 28, 2023 |
| Alembic Pharmaceuticals Limited | 4 | injection | Generic drugs (ANDA) | February 28, 2023 |
| BluePoint Laboratories | 4 | solution; injection | Generic drugs (ANDA) | April 1, 2026 |
| Amneal Pharmaceuticals LLC | 3 | injection | Generic drugs (ANDA) | January 19, 2018 |
| Avyxa Pharma, LLC | 3 | injection, solution | New drug applications (NDA) | May 9, 2024 |
| Eugia US LLC | 3 | injection, solution | Generic drugs (ANDA) | June 25, 2021 |
| Hikma Pharmaceuticals USA Inc. | 3 | injection, solution, concentrate; injection | Generic drugs (ANDA) | June 28, 2024 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 3 | injection, solution, concentrate | Generic drugs (ANDA) | August 9, 2017 |
| Mylan Institutional LLC | 3 | injection, solution | Generic drugs (ANDA) | August 3, 2022 |
| Natco Pharma USA LLC | 3 | injection, solution | Generic drugs (ANDA) | November 7, 2024 |
| Novadoz Pharmaceuticals LLC | 3 | injection, solution | Generic drugs (ANDA) | August 26, 2020 |
| Sagent Pharmaceuticals | 3 | injection, solution; injection | Generic drugs (ANDA) | February 1, 2024 |
| Sanofi-Aventis U.S. LLC | 3 | injection, solution, concentrate | Authorized generics (NDA) | October 23, 2016 |
| Sun Pharmaceutical Industries, Inc. | 3 | injection, solution | New drug applications (NDA) | November 26, 2020 |
| Actavis Pharma, Inc. | 2 | injection, solution, concentrate | New drug applications (NDA) | September 1, 2014 |
| Apotex Corp. | 2 | injection | Generic drugs (ANDA) | March 19, 2025 |
| Hospira, Inc. | 2 | injection, solution | Generic drugs (ANDA) | April 8, 2025 |
| NorthStar RxLLC | 2 | solution; injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | December 5, 2025 |
| Sandoz Inc | 2 | injection, powder, lyophilized, for suspension; injection | Generic drugs (ANDA) | July 7, 2025 |
| Zhuhai Beihai Biotech Co., Ltd. | 2 | injection, solution | New drug applications (NDA) | December 15, 2025 |
| Zydus Pharmaceuticals USA Inc. | 2 | injection, solution | New drug applications (NDA) | December 15, 2025 |
| Abraxis BioScience, LLC | 1 | injection, powder, lyophilized, for suspension | New drug applications (NDA) | February 10, 2005 |
| Accord Healthcare Inc. | 1 | injection, solution, concentrate | New drug applications (NDA) | May 30, 2013 |
| Almirall, LLC | 1 | ointment | New drug applications (NDA) | December 14, 2020 |
| American Regent, Inc. | 1 | injection, powder, lyophilized, for suspension | New drug applications (NDA) | May 2, 2023 |
| BSP Pharmaceuticals S.p.A. | 1 | injection | New drug applications (NDA) | April 21, 2017 |
| Baxter Healthcare Company | 1 | injection | Generic drugs (ANDA) | October 1, 2024 |
| Bryant Ranch Prepack | 1 | injection, solution | Generic drugs (ANDA) | August 26, 2020 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 | injection | Generic drugs (ANDA) | March 4, 2025 |
| Cipla USA Inc. | 1 | injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | April 15, 2025 |
| Eisai Inc. | 1 | injection | New drug applications (NDA) | November 15, 2010 |
| Exelan Pharmaceuticals Inc. | 1 | injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | August 11, 2026 |
| Fresenius Kabi USA, LLC | 1 | injection, solution | Generic drugs (ANDA) | March 20, 2009 |
| Glenmark Pharmaceuticals Inc., USA | 1 | injection | Generic drugs (ANDA) | August 5, 2025 |
| Kindos Pharmaceuticals Co., Ltd. | 1 | injection | Generic drugs (ANDA) | August 5, 2025 |
| Long Grove Pharmaceuticals, LLC | 1 | solution | Generic drugs (ANDA) | July 22, 2024 |
| Ningbo Shuangcheng Pharmaceutical Co., Ltd | 1 | injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | May 15, 2025 |
| NorthStar Rx LLC | 1 | injection, solution | Generic drugs (ANDA) | January 25, 2021 |
| Sandoz Inc | 1 | injection, solution | New drug applications (NDA) | June 29, 2011 |
| Sun Pharmaceutical Industries, Inc. | 1 | injection | Generic drugs (ANDA) | May 15, 2025 |
| Teva Pharmaceuticals, Inc. | 1 | injection, powder, lyophilized, for suspension | New drug applications (NDA) | July 2, 2024 |
| XGen Pharmaceuticals DJB, Inc. | 1 | injection | Generic drugs (ANDA) | April 7, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 60 | 45.1% |
| Injection | 37 | 27.8% |
| Injection, solution, concentrate | 21 | 15.8% |
| Injection, powder, lyophilized, for suspension | 11 | 8.3% |
| Solution | 3 | 2.3% |
| Ointment | 1 | 0.8% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.